past
sever
decad
advanc
eman
basic
research
substanti
proport
support
us
nation
institut
health
nih
transform
almost
everi
disciplin
biomed
scienc
includ
field
infecti
technic
advanc
field
genom
proteom
synthet
chemistri
robot
comput
model
molecular
genet
epidemiolog
inform
technolog
yield
unpreced
new
insight
diseas
pathogenesi
host
immun
pathogen
virul
transmiss
pattern
drug
advanc
facilit
discoveri
design
new
vaccin
diagnost
treatment
intervent
import
part
reduc
burden
infecti
diseas
exampl
develop
licens
medic
human
immunodefici
viru
hiv
greatli
reduc
hivrel
morbid
mortal
set
drug
list
vaccineprevent
diseas
grown
licensur
vaccin
pathogen
streptococcu
pneumonia
haemophilu
influenza
type
b
hepat
b
virus
improv
vaccin
mani
therapeut
vaccin
candid
research
pipelin
treat
prevent
diseas
caus
endem
pathogen
emerg
reemerg
microb
avian
influenza
viru
potenti
agent
bioterror
dramat
growth
scienc
base
infecti
diseas
began
golden
year
nih
fund
time
support
biomed
research
commun
seem
strong
momentum
establish
subsequ
research
advanc
area
recombin
dna
technolog
truli
extraordinari
compound
possibl
even
greater
accomplish
doubl
overal
nih
budget
fiscal
year
fy
fy
billion
provid
anoth
big
boost
fig
nih
fy
budget
billion
throughout
budgetari
number
nih
nih
offic
budget
http
officeofbudgetodnihgovuihomepagehtm
nation
institut
allergi
infecti
diseas
niaid
provid
niaid
offic
financi
manag
person
commun
except
otherwis
indic
term
budget
appropri
niaid
lead
nih
agenc
infecti
diseas
research
fare
even
better
nih
whole
fy
niaid
fifthlargest
nih
institut
term
budget
million
fy
niaid
secondlargest
nih
institut
estim
budget
billion
much
budget
growth
niaid
attribut
larg
increas
spend
hivaid
million
fy
billion
fy
biodefens
research
million
fy
billion
fy
largerthanaverag
increas
budget
emerg
reemerg
infecti
diseas
clearli
infecti
diseas
research
commun
fare
well
term
nih
support
policymak
taxpay
recogn
research
global
infecti
diseas
deserv
robust
support
axiomat
live
global
commun
microb
recogn
border
must
address
infecti
diseas
threat
regardless
geograph
hivaid
fund
alon
estim
billion
fy
compris
total
nih
budget
approxim
one
third
niaid
budget
increas
come
expens
nih
support
area
infecti
diseas
increas
nonaid
infecti
diseas
immunolog
increas
mean
increas
nih
whole
past
decad
level
fund
certainli
well
justifi
enorm
medic
public
health
societ
challeng
pose
hivaid
pandem
unpreced
scientif
opportun
effect
live
peopl
throughout
world
cours
pandem
improv
understand
hiv
pathogenesi
develop
new
improv
approach
treatment
prevent
care
howev
factor
converg
signal
chang
largess
biomed
research
us
becom
accustom
nation
collect
tighten
belt
reduc
feder
debt
project
exceed
trillion
end
fy
ref
enter
new
period
fiscal
constraint
becom
known
postdoubl
era
disciplin
includ
hivaid
infecti
diseas
well
major
diseas
heart
diseas
cancer
affect
unlik
approxim
annual
increas
seen
nih
fund
fy
fy
nih
budget
increas
fy
fy
niaid
fare
slightli
better
nih
whole
tabl
fy
propos
nih
budget
increas
less
nih
overal
slightli
larger
niaid
fund
tabl
note
project
budget
increas
keep
pace
biomed
inflat
repres
biomed
research
develop
price
annual
index
project
increas
year
fy
fy
ref
superimpos
new
budget
realiti
addit
challeng
includ
continu
emerg
reemerg
infecti
diseas
sever
acut
respiratori
syndrom
sar
west
nile
viru
avian
influenza
virus
pandem
potenti
demand
attent
fig
addit
grow
expect
part
administr
congress
gener
public
deliver
countermeasur
use
realworld
set
prevent
amelior
diseas
presidenti
mandat
research
develop
prevent
hiv
vaccin
countermeasur
potenti
agent
bioterror
high
prioriti
past
prologu
almost
year
ago
nih
face
equal
sober
budget
situat
time
wrote
resourc
biomed
research
gener
unlik
increas
substanti
forese
futur
area
constrain
yet
opportun
advanc
knowledg
practic
applic
advanc
sure
increas
henc
dichotomi
aspir
resourc
probabl
widen
make
best
use
avail
resourc
limit
gap
aspir
resourc
toptobottom
examin
everi
nih
research
portfolio
undertaken
prepar
possibl
substanti
budget
decreas
enlighten
see
mani
area
research
could
carri
effici
fortun
budget
decreas
expect
come
pass
thank
deu
ex
machina
form
advocaci
effort
congression
administr
leadership
result
aforement
doubl
nih
nihfund
investig
especi
infecti
diseas
research
enjoy
substanti
annual
budget
increas
help
facilit
import
advanc
pathogenesi
natur
histori
epidemiolog
behavior
social
scienc
vaccin
develop
inde
younger
investig
area
hivaid
infecti
diseas
fortun
work
entir
career
rel
unfett
fiscal
constraint
typifi
era
biomed
research
fund
area
nihfund
research
infecti
diseas
research
includ
hivaid
research
portfolio
face
realiti
constrain
level
fund
hiv
research
hiv
vaccin
research
project
see
substanti
increas
fy
ref
select
increas
hiv
vaccin
research
fund
reflect
consensu
safe
effect
vaccin
hiv
essenti
curb
global
hiv
fund
biodefens
research
increas
substanti
septemb
attack
us
subsequ
bioterror
event
involv
anthrax
spore
dissemin
via
us
mail
howev
period
fy
fy
nih
biodefens
fund
like
overal
infecti
diseas
fund
level
rel
constant
amount
billion
notabl
exampl
hivaid
biodefens
typic
emerg
reemerg
diseas
infecti
diseas
threat
perceiv
seriou
threat
year
two
west
nile
viru
sar
drive
budget
signific
sustain
way
compar
hivaid
pandem
rage
bioterror
perceiv
indefinit
substanti
nih
fund
base
biodefens
like
hivaid
like
maintain
forese
futur
togeth
fund
base
infecti
diseas
gener
new
era
fiscal
constraint
look
ahead
niaid
budget
beyond
fy
anticip
annual
budget
increas
less
annual
increas
cost
basic
research
grant
roi
grant
averag
annual
increas
research
project
grant
rpg
applic
ref
import
challeng
niaid
reconcil
number
find
way
preserv
robust
commit
fundament
investigatoriniti
research
bedrock
research
enterpris
meet
expect
appli
research
includ
advanc
develop
vaccin
therapeut
key
postdoubl
niaid
goal
maintain
minimum
base
compet
rpg
award
year
fy
latest
year
final
figur
avail
niaid
fund
compet
award
regardless
budget
constraint
feel
imper
fall
threshold
rpg
avoid
turn
faucet
innov
fed
basic
research
howev
maintain
level
award
per
year
need
take
unfamiliar
measur
almost
certainli
niaid
along
nih
whole
longer
abl
provid
investig
yearli
inflationari
increas
grant
fund
may
need
reduc
averag
dollar
amount
new
award
addit
success
rate
proport
grant
applic
receiv
fund
drop
fy
period
fy
fy
cours
remain
essenti
us
medic
public
health
commun
continu
argu
cogent
adequ
attent
sustain
research
support
diseas
global
health
import
public
health
challeng
face
us
substanti
scientif
opportun
true
breakthrough
abound
time
must
collect
prepar
difficult
question
pose
frequent
policymak
public
challeng
perceiv
research
entitl
well
fund
area
inquiri
hivaid
research
question
ask
congression
hear
meet
administr
offici
brief
constitu
group
includ
follow
spend
larg
bolu
money
alreadi
receiv
set
prioriti
accomplish
even
increas
effici
research
yield
product
benefit
health
american
peopl
today
budget
environ
administr
congress
public
expect
us
continu
examin
research
enterpris
word
sacr
cow
exempt
scrutini
review
frequent
ask
role
head
nih
institut
largest
portion
hivaid
research
portfolio
whether
hivaid
fund
cut
especi
given
fact
diseas
occupi
fulli
one
third
niaid
budget
answer
almost
certainli
given
recognit
white
hous
member
congress
side
aisl
gener
public
hivaid
plagu
histor
certainli
cut
hivaid
fund
part
niaid
strateg
howev
hivaid
infecti
diseas
need
make
best
avail
fund
reexamin
busi
sever
necessari
step
must
taken
fig
first
must
strive
collabor
better
cooper
among
investig
govern
industri
academia
philanthrop
organ
eye
toward
harmon
improv
economi
scale
mani
infecti
diseas
disciplin
probabl
elimin
redund
clinic
trial
network
also
must
standard
assay
reagent
endpoint
result
investig
broadli
relev
entir
field
rather
subset
research
group
chosen
particular
set
also
imper
elimin
unnecessari
duplic
research
enterpris
extent
possibl
mani
time
duplic
import
inde
necessari
confirm
research
find
unnecessari
duplic
unaccept
time
fiscal
constraint
maxim
finit
resourc
time
scientif
aspir
opportun
nearli
infinit
infecti
diseas
investig
govern
academia
industri
must
necess
collabor
use
medic
countermeasur
reach
market
one
sector
singlehandedli
address
complex
scientif
technic
social
econom
polit
challeng
involv
product
crosssector
collabor
extraordinari
success
achiev
includ
recent
licens
vaccin
antiretrovir
medic
strike
balanc
note
face
increas
expect
deliver
challeng
balanc
basic
research
advanc
product
develop
set
fiscal
constraint
throughout
scientif
train
taught
still
believ
import
place
scientia
gratia
scientia
scienc
sake
scienc
scientif
endeavor
fundament
research
driven
scientist
curios
interest
scientif
question
alway
central
tenet
scientif
inquiri
even
cursori
look
histori
biomed
research
remind
us
import
scientif
breakthrough
invari
achiev
openend
inquiri
niaid
alway
support
fundament
research
gener
new
knowledg
diseas
work
translat
find
vaccin
therapeut
diagnost
protect
public
howev
rapidli
develop
safe
effect
product
ask
govern
provid
fund
intensifi
acceler
process
expens
basic
research
portfolio
thu
sought
creativ
way
modifi
tradit
process
research
develop
move
rapidli
ahead
continu
preserv
excel
basic
research
hallmark
nih
work
close
collabor
industri
academia
taken
much
proactiv
role
move
promis
idea
advanc
product
develop
exampl
project
bioshield
act
provid
power
new
mechan
expedit
develop
deploy
medic
countermeasur
bioterror
ref
depart
health
human
servic
project
bioshield
http
wwwosdhhsgovophepbioshield
bioshield
give
nih
addit
flexibl
award
contract
cooper
agreement
grant
research
develop
critic
medic
countermeasur
streamlin
scientif
evalu
biodefens
research
propos
bioshield
also
provid
industri
assur
market
product
exist
invest
resourc
necessari
fulli
develop
help
provid
incent
bioshield
establish
secur
fund
sourc
purchas
stockpil
new
vaccin
drug
use
emerg
thu
bioshield
given
us
new
way
push
pull
scienc
toward
need
countermeasur
basic
research
provid
push
new
incent
industri
product
develop
provid
pull
project
bioshield
may
repres
new
model
entic
industri
particip
develop
product
profit
market
assur
emblemat
broader
shift
role
nih
advanc
product
develop
increasingli
nih
niaid
expand
role
beyond
tradit
area
basic
preclin
smallscal
research
advanc
product
develop
use
mechan
vaccin
product
contract
new
partnership
fig
approach
transcend
hivaid
biodefens
appli
countermeasur
broad
rang
infecti
diseas
context
niaid
vaccin
research
center
proven
extraordinarili
success
model
develop
vaccin
pathogen
hiv
sar
coronaviru
smallpox
viru
west
nile
viru
take
idea
basic
research
product
pilot
lot
conduct
clinic
trial
nation
institut
allergi
infecti
diseas
dale
betti
bumper
vaccin
research
center
http
wwwniaidnihgovvrc
niaid
also
bolster
portfolio
research
resourc
provid
academ
industri
partner
prime
pump
product
develop
research
resourc
manag
institut
extramur
research
divis
divis
allergi
immunolog
transplant
http
wwwniaidnihgovresearchdaithtm
divis
acquir
immun
defici
syndrom
http
wwwniaidnihgovdaid
divis
microbiolog
infecti
diseas
http
wwwniaidnihgovdmid
includ
reagent
repositori
genom
databas
anim
model
clinic
trial
support
resourc
new
model
collabor
promis
optim
search
critic
countermeasur
enhanc
coordin
inform
share
collabor
global
hiv
vaccin
enterpris
virtual
consortium
network
collabor
institut
establish
priorit
scientif
challeng
address
hiv
vaccin
develop
fill
gap
enterpris
seek
stimul
research
fund
research
explor
new
collabor
cooper
transpar
approach
address
main
obstacl
hiv
vaccin
develop
addit
continu
product
highqual
program
alreadi
underway
anoth
exampl
niaid
restructur
aid
clinic
trial
network
maxim
scientif
opportun
accomplish
integr
prevent
treatment
research
improv
effici
build
strengthen
research
capac
especi
resourcelimit
set
improv
account
evalu
method
divis
aid
clinic
trial
network
fy
http
conclus
realiti
steadyst
fund
infecti
diseas
research
one
must
face
collect
enjoy
unpreced
scientif
opportun
success
previou
present
endeavor
make
opportun
time
fiscal
constraint
must
rigor
examin
reanalyz
research
portfolio
strive
increas
transpar
standard
collabor
harmon
greater
economi
scale
less
unnecessari
redund
world
expect
deliver
must
push
tangibl
result
product
without
compromis
greatest
asset
individu
creativ
basic
research
investig
